Noncoding RNAs endogenously rule the cancerous regulatory realm while proteins govern the normal.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

6 citing papers in PubMed.

1. Ferroptosis as a Novel Therapeutic Strategy to Overcome Multidrug Resistance in Colorectal Cancer.Pharmaceuticals (Basel, Switzerland) · 2026
   Review
2. The Primary Role of Noncoding RNA in the Pathogenesis of Cancer.Genes · 2025
   Review
3. Noncoding RNAs evolutionarily extend animal lifespan.Global medical genetics · 2025
   Article
4. Conceptual breakthroughs of the long noncoding RNA functional system and its endogenous regulatory role in the cancerous regime.Exploration of targeted anti-tumor therapy · 2024
   Review
5. Noncoding RNAs and Deep Learning Neural Network Discriminate Multi-Cancer Types.Cancers · 2022
   Article
6. Distinctive functional regime of endogenous lncRNAs in dark regions of human genome.Computational and structural biotechnology journal · 2022
   Article

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

Authors and funding

1 author.

Funding

No grant is acknowledged in the PubMed record.

Abstract

Indexed as